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Abstract
Behcet’s disease (BD) is a multisystemic inflammatory vasculitic disorder which diag-
nosed by clinical criteria because of the lack of specific laboratory test and/or pathogno-
monic histopathological findings. The most frequent diagnostic criteria of this disease 
are mucocutaneous lesions, appearing at the disease onset or during the course, usually 
begin before significant organ dysfunction. According to BD International Study Group 
Criteria, one of the five criteria is dermatologic findings including pseudofolliculitis, 
acneiform nodules or papulopustular lesions (PPL) diagnosed by clinician in postadoles-
cent patients. In some case reports and clinical studies, the PPL of BD are also denoted 
as Behcet’s pustulosis, folliculitis, acneiform eruptions and pseudofolliculitis. Owing to 
implementation of follicular lesions in these criteria, there may be difficulties in the dis-
tinction between most of the PPL of BD and the other acneiform eruptions/nonspecific fol-
licular lesions (e.g., acne vulgaris, bacterial folliculitis, steroid acne). Certainly, clinicians 
should distinguish these patterns for accurate diagnosis. Although earlier studies involve 
numerous quandaries regarding the diagnostic histopathologic pattern of BD (e.g., 
whether to include vasculitis or nonspecific folliculitis), it was reported recently that the 
determination of vasculitic changes in histopathological and direct immunofluorescence 
results might be useful in the differential diagnosis of patients suspected to have BD.
Keywords: Behcet’s disease, acneiform eruption, papulopustular lesion, 
pseudofolliculitis
1. Introduction
Acneiform eruptions have a broad clinical spectrum, where they differ via lesion location and 
morphology. Certainly, clinicians should distinguish these patterns for accurate  diagnosis. One 
of the differential diagnoses in acneiform papulopustular lesions (PPL) is Behcet’s  disease (BD), 
and it should have been firstly recognized, particularly around the Silk Route region [1, 2].
© 2017 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
BD is a multisystemic vasculitic disorder that is characterized by recurrent oral aphthous 
ulcerations, genital ulcerations, mucocutaneous manifestations, uveitis, and a positive 
pathergy test. Additionally, later studies showed that the vasculitic pattern has shown articu-
lar, gastrointestinal, urogenital, neurological, pulmonary, and cardiac involvement. This dis-
ease has a chronic course with unpredictable exacerbations and remissions [1, 3, 4].
In 1937, Prof. Dr. Hulusi Behcet (1889–1948), who was a great scientist and the first professor 
in Turkey, diagnosed this disease as a trisymptom complex consisting of aphthous ulcer-
ations, genital ulcerations, and ocular involvement. In the ancient literature, some authors 
named the disease as Adamantiades-Behcet disease. Adamantiades was an ophthalmologist 
who insisted on “relapsing iritis with hypopyon” in BD. Prof. Dr. Hulusi Behcet insisted on 
a complex multisystemic synonym, not only ocular involvement. As an honor to Turkish 
Medical history, the disease was renamed as “Maladie de Behcet,” as it is known today [5].
BD is mainly distributed along the Silk Route region, with higher prevalence in the 
Mediterranean, the Middle East, and the Far East countries. Turkey has the highest prevalence, 
with about 80–370 cases per 105 population. This disease usually begins around the third or 
fourth decade of life. Globally, female and male distribution rates are equal. Although, if we 
want to categorize by geographical areas, BD shows male predominance in some Middle 
Eastern and Mediterranean countries and female predominance in Japan and Korea. Male 
predominance and young onset usually have worse prognosis [1, 6].
The etiology of BD has not yet been fully elucidated, but the strongest genetic susceptibility is 
HLAB51 or HLAB5. It has been demonstrated that in some studies, herpes simplex virus and 
streptococcus sanguinis/pyogenes activate innate and adaptive immunity so that a neutro-
philic vasculitic reaction occurs. Additionally, some authors reported that interleukin (IL)-23 
and IL-12 share p40 subunits and induce the IL17 pathway. Induced IL-17 and T-helper 17 
levels activate oral ulcerations, genital ulcerations, and articular involvements [1, 7].
2. Diagnosis/classification criteria for BD
Due to a lack of distinctive diagnostic laboratory tests, the diagnosis of BD is based on certain 
clinical criteria. From onset of the disease, diagnosis time has taken approximately 8 years. 
Based on that, several criteria have been established during the years, all consist of three 
major criteria, including oral ulceration, genital ulceration, and eye lesions [1, 8, 9].
First of all, in 1969, Mason and Barnes identified major criteria (oral ulceration, genital ulcer-
ation, eye lesions, skin lesions) and minor criteria (gastrointestinal lesions, thrombophlebitis, 
cardiovascular lesions, arthritis, central nervous system lesions, family history), and then sug-
gested that to make the diagnosis of BD, a minimum of three major, or two major and two minor 
criteria were required [10]. After that, in 1972, the Behcet’s Disease Research Committee of Japan 
answered with a different set of criteria more suitable for their population. In order to get a new 
point of view, O’Duffy [11] published another criteria in 1974 for Japanese national criteria [12].
In 1990, criteria that were later accepted worldwide were developed by an International Study 
Group at the fourth International Conference on BD in London. The most specific and  sensitive 
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guide that clinicians have used globally for years is demonstrated in Table 1. To make BD 
diagnosis, the presence of major and two minor criteria is considered to be adequate [13].
Lastly, International Criteria for Behcet’s Disease was also renewed in 2010, which is occasion-
ally prevalent in Iran. In this point score system, the criteria (ocular lesions, genital aphthous 
ulcerations, and oral aphthous ulcerations, each of them 2 points; skin lesions, neurological 
manifestations, vascular manifestations, and positive pathergy test, each of them 1 point; and 
scoring ≤4 indicates BD) should not be seen as a part of universal agreement but also have 
chance to criticize the sensitive ones [8].
Among the many quandaries, the International Study Group criteria and the International 
Criteria for Behcet’s Disease were configured in different cohorts. Davatchi et al. analyzed Iranian 
BD patients by using the International Study Group criteria versus International Criteria for 
Behcet’s Disease. These authors found that International Criteria for Behcet’s Disease sensitivity 
was 98.2% (78.1% with International Study Group criteria), the specificity was 95.6% (98.8% with 
International Study Group criteria), and the accuracy was 97.3% (85.5% with International Study 
Group criteria) [14]. Moreover, Leonardo and McNeil mentioned that the International Criteria 
for Behcet’s disease has higher sensitivity and less specificity due to the fact that they evaluated 
data from 27 countries. They also said that those studies emphasized that International Criteria for 
Behcet’s Disease can be an easier tool for diagnosis but also may cause overdiagnosis [6].
3. Clinical features of BD
As we mentioned before, the constant diagnostic feature of BD is oral ulcerations. Additionally, 
other factors occasionally depend on the  dermatologist. Thus,  mucocutaneous lesions are a 
Major criteria BD diagnosis Minor criteria
Recurrent oral ulceration 
Minor aphthous, major aphthous, or 
herpetiform ulceration observed by 
physician or patient recurring at least 
three times in one 12-month period
Major criteria plus any 
two of the minor criteria
Recurrent genital ulceration
Aphthous ulceration or scarring observed by 
physician or patient 
Eye lesions 
Anterior uveitis, posterior uveitis, cells in the 
vitreous on slit-lamp examination; or retinal 
vasculitis observed by ophthalmologist 
Skin lesions 
Erythema nodosum observed by the physician 
or patient; pseudofolliculitis or papulopustular 
lesions; or acneiform nodules observed by physician 
in postadolescent patients not on corticosteroid 
treatment 
Pathergy test 
Test interpreted as positive by physician at 24–48 
hours
Table 1. International Study Group diagnostic criteria of Behcet’s diseasexs.
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“ hallmark of the disease.” Oral ulcerations are the most  common  manifestation, followed by 
genital ulcerations, mucocutaneous lesions, skin pathergy reaction, and articular and ocular 
involvement [1, 9].
Recurrent oral aphthous ulcerations are the most common and significant criteria in diagno-
sis, constituting “fingerprint” of BD. They are characterized by painful ulcerations in non-
keratinized mucous membranes such as lips, tongue, gingiva, buccal mucosa or vestibulum. 
Typically, oral aphthous ulcerations have recurred at least three times over a 1-year period. 
On the onset of the lesion, slightly elevated erythematous area with a vesiculopustular lesion 
that changed to an ulceration with well-defined borders and greyish yellow necrotic base in 
24–48 hours. Oral ulcerations can be divided into three types: minor, major, and herpetiform. 
Major and herpetiform types may cause scarring formation [9, 15].
Genital ulcerations are the second most common clinical finding and are similar to oral ulcer-
ations. Mostly, it begins with fragile papule or nodule, after that becomes ulceration area. 
They are usually located in labia minor, labia major, and vagina for women, and penis and 
scrotum in men. They are seen as deeper lesions and also heal slowly with scarring. The 
patients also have fistulas between urethra and bladder that may cause dyspareunia, severe 
pain, and difficulty of urination [1, 2, 9].
The most common type of mucocutaneous features is PPL. In addition, these lesions may 
occasionally occur following erythema nodosum-like lesions, superficial thrombophlebitis, 
skin pathergy test, extragenital ulceration, and Sweet’s syndrome-like lesions. Subungual 
infarctions, hemorrhagic bullae, furuncles, abscesses and acral purpuric papulonodular 
lesions and also pyoderma gangrenosum-like lesions, erythema multiforme-like lesions, per-
nio-like cutaneous lesions, Henoch-Schsönlein purpura and bullous necrotizing vasculitis can 
also be seen in some case reports of BD [1, 9, 15].
4. PPL in BD
In some case reports and clinical studies, the PPL of BD are also denoted as Behcet’s pustulosis, 
folliculitis, acneiform eruptions, and pseudofolliculitis. Clinicians may find papules, pustules, 
nodules, and also comedones in some BD patients [16–20]. It usually starts as a papule with 
erythematous base that changes to a pustule in 24–48 hours (Figure 1). The PPL of BD mainly 
stay on the trunk and extremities, except for the palms and soles, where there is a surplus 
sebum production and hair follicle, but also similar to acne vulgaris they have been occasion-
ally seen on the face. As a point of view, pustules are common in both diseases but microbio-
logical specimens are not similar so that it could be a clue for differential diagnosis [7, 21].
Since BD is a neutrophilic dermatosis, histopathologic findings of PPL include neutrophilic 
vasculitis and both of the lymphocytic and leukocytoclastic types in late onset, together. 
However, some authors found only perifollicular and perivascular mononuclear, or neutro-
philic infiltrations in PPL of BD; they could not detect vasculitis [22–27].
BD is an autoinflammatory disease that is qualified by primary dysfunction of the innate 
and adaptive immune system such as neutrophil hyper-reactivity and T-lymphocytes hyper-
sensitivity to some antigens. In some research studies, increased cytokine and chemokine 
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levels are also found in blood samples. Nonetheless, the mechanism underlying these skin 
lesions remained elusive. Furthermore, investigations have continued during years in order 
to explain the immunological mechanism. In the beginning in adaptive immune system, cyto-
toxic T-lymphocytes have been demonstrated as significant effector cells in BD. Cytotoxic 
T-lymphocytes have been expressed granulysin, which is a cytolytic granule protein. Yamasaki 
et al. investigated granulysin levels in mucocutaneous lesions of BD by ELISA technique. They 
found strong expression of granulysin levels in CD4+ and CD8+ T-lymphocytes infiltrating 
acne-like eruptions. As a result, they suspect that granulysin positive cytotoxic T-lymphocytes 
may have a significant role in the pathogenetic mechanism for acneiform eruptions [28]. At 
genetic levels, it is known to have common associations with higher HLA B51 subtypes. 
Park et al. determined the association of a certain polymorphism (C438T) of the SUMO4 
gene with HLA B51 positive BD patients in Korea. Small ubiquitin-like modifier has been 
referred as SUMO4 that downregulate the transcription activity of nuclear factor–kappa B. 
They found that the C438T polymorphism in the SUMO4 gene is associated with a  significantly 
Figure 1. (a) Erythematous papulopustular lesions on chest region (upper trunk) and (b) erythematous papulopustular 
lesions on pectoral region (upper trunk).
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increased risk of PPL in HLA-B51-positive BD patients [29]. Moreover, Demirseren et al. 
 configured out the association between the subtypes of HLA-B51. Much interesting data are 
HLA-B5109 subtype was found to be less frequent in patients with PPL in BD. Thus, the 
HLA-B5109 subtype could be protective against acneiform eruptions [30]. Finally, Cho et al. 
detected the immunophenotypes of the common BD-related skin lesions and evaluated the 
expression of cytokines and composition of the infiltrating cells. In PPL, neutrophils were the 
most commonly infiltrated type and followed by CD8+ T cells, despite the fact that it was not 
found as statistically significant. Also, percentage of CD8+ T cells was significantly more than 
FoxP3.These authors recognized that IL-4 levels were also higher than the interferon (IFN) 
levels so that the adaptive immune system plays a major role in PPL [31].
4.1. Frequency of PPL in BD
In the diagnosis of BD, the primary aim is to find early diagnostic clues to prevent sys-
temic involvement. For dermatologists, PPL has significant role in these diagnostic crite-
ria. According to International Study Group, data of the chosen patients demonstrated as 
sensitivity and specificity of these lesions were 70% and 76%, respectively [13]. However, 
the sensitivity and specificity of PPL were found to be 96% and 11% by Alpsoy et al., so 
it depends on the experience of the clinician. They suggested that PPL is very sensitive 
but not specific, so the location of lesions is more important for differentiation from other 
diseases [22].
Based on a literature review, it may be said that the frequencies of PPL in BD patients range 
from 12% to 96%, varying greatly from country to country, as demonstrated in Table 2. [14, 
16–20, 22, 29, 30, 32–46]. There are many studies consisting BD patients in Turkey, which is 
one of the most common country in terms of BD frequency varying between 39.6% and 75% 
[22, 30, 34–37, 41, 42]. National-based surveys were evaluated to understand the global pat-
tern of the disease. Some authors analyzed five nationwide surveys of BD in Iran with 5059 
patients, Japan with 3316 patients, China with 1996 patients, Korea with 1527 patients, and 
Germany with 590 patients. It was shown that PPL have varying proportion in terms of inci-
dence in different regions, such as 62% in Germany, 57% in Iran, and 31% in China. These 
results were interpreted to mean that immigrations have changed the value of the Silk Route 
Region pattern [47].
The evaluation and differentiation of PPL in 65 patients were considered by Hamdan et al.; 
they found that 49 patients (55.7%) had PPL, including 25 (28.4%) with acneiform lesions, 17 
(19.3%) with pseudofolliculitis, 4 (4.4%) with pustular eruptions, and 3 (3.3%) with nonspe-
cific subcutaneous nodules and rashes. According to this point of view, acneiform lesions are 
the most common type of PPL so clinicians should take special care to distinguish them from 
acne vulgaris [16]. According to some previous studies, male patients have more frequent 
PPL than females and their prognosis was worse [17–20, 29, 35, 36, 39, 41, 43, 46]. Bonitsis et 
al. [43] has already clarified these results via a meta-analysis study of a German population. 
Some authors speculated that the main reason of provoking PPL in males may be related with 
testosterone levels. Durusoy et al. [48] indicated that androgens may play a role at least in the 
formation of PPL and disease activity in patients with BD.
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in BD (%) (different 
terms used in 
literature)
Comparisons according to 
certain variables
Alpsoy et al. [22] Turkey (–1998) 50 PPL: 96% –
Zouboulis et al. [32] Germany (1990–2000) 347 PPL: 53% –
Shahram et al. [33] Iran (–2001) 4704 PPL: 62% –
Azizlerli et al. [34] Turkey (–2003) 101 PF: 39.6% Male vs female: 55% vs 45%
Tursen et al. [35] Turkey (1976–98) 2313 PPL: 54% Male vs female: 56.1% vs 43.9%*
Hamdan et al. [16] Lebanon (1977–2005) 90 PPL: 55.7% (28.4% 
with acneiform 
lesions, 19.3% with 





Male vs female: 59.1% vs 45.5%
Houman et al. [17] Tunisia (1987–2006) 260 PF: 70.4% Male vs female: 75.5% vs 58.3%* 
Ocular lesions (+) vs (–): 69.8% vs 
71.6% BD-DVT (+) vs (–): 70.9% 
vs 70.5% BD Neuro (+) vs (–): 
61.9% vs 73.6%
Alpsoy et al. [36] Turkey (2007) 661 PPL: 55.4% Male vs female: 62% vs 44.3%*
Alli et al. [37] Turkey (2001–2004) 213 PPL: 56% Male vs female: 63.5% vs 49.5%*
Arida et al. [18] Greece (2000–2008) 142 PF: 44.4% Male vs female: 61.3% vs 22.6%*
Vaiopoulos et al. [19] Greece (1991–2007) 202 PF: 1.5% as onset 
sign, 5.9% as second 
symptom
Male vs female: 57.1% vs 21.9%*
Davatchi et al. [14] Iran (1975–2010) 6500 PF: 54.5% Age groups: <21: 57.0%, 21–40: 
54.9%, 41–60: 40.4%, >60: 63.6%
Oliveira et al. [20] Brazil (2011) 60 PPL: 23.3%, acne-like 
lesions: 6.7%
Male vs female: 40.7 vs 9.1%*
Park et al. [29] Korea (2012) 83 PPL: 56.6% HLA-B51 (+) vs (–):35.7 vs 67.3%*
Singal et al. [38] India (1997–2011) 29 PPL and acneiform 
lesions: 31%
Hamzaoui et al. [39] Tunisian (1989–2009) 430 PF: 74.4% Age < 20: 84%, age > 40: 63.2%*
Sula et al. [40] Southeastern Turkey 
(2005–2009)
132 PPL: 74.2% Male vs female: 76.7 vs 72.3%
Balta et al. [41] Turkey (–2014) 521 PPL: 61.0% Male vs female: 71.4 vs 52.6%*
Ugurlu et al. [42] Turkey (2001–2012) 368 PPL: 75.0% Male vs female: 80.7 vs 68.4%
Bonitsis et al. [43] Germany (1990–2012) 747 PPL: 46.6%, PF: 47.2% PPL: Male vs female: 50.6 vs 
41.1%*PF: Male vs female: 52.2 
vs 40.1% *
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One study focused on the relationship between age and the frequency of diagnostic criteria. 
In this study, Hamzaoui et al. separated patients into two groups who were less than 20 years 
old and more than 40 years old. It was found that cutaneous involvement and pseudofollicu-
litis were significantly more common in younger age group. However, joint involvements in 
the older group were more frequent, which is controversial regarding the frequent association 
between PPL and arthritis [39].
4.2. PPL accompanied by some clinical features in BD
Clinicians should suspect some clinical findings that frequently accompany PPL to facilitate 
a correct diagnosis. Of these situations, the most known is arthritis. Diri et al. determined 
acneiform eruptions and relationship of arthritis and BD through evaluating four groups 
consisting of 44 BD patients with arthritis, 42 BD patients without arthritis, 21 patients with 
active rheumatoid arthritis and 33 healthy volunteers. They reported that only the BD with 
arthritis group had significantly higher PPL. As a conclusion, arthritis and acneiform lesions 
may have same pathogenesis so that they occasionally appear together [49]. Moreover, Karaca 
et al. argued that PPL and arthritis have an inherited pathogenesis. Likewise, they found BD 
appears as cluster in familial BD constantly. They also suggested a mechanism that works 
on the same bacterial pathway responsible for this association [50]. Calgüneri et al. [51] also 
manifested that prophylactic penicillin treatment alleviated both acneiform eruptions and 
arthritis attacks. In another study, Fatemi et al. investigated articular involvement in BD. They 
emphasized that PPL was higher during episodes of arthritis, and in episodic attacks, only the 
presence of PPL as an extra-articular involvement was statistically meaningful [45].
The pathergy test had been researched as another entity. Arida et al. found positive correla-
tion between pathergy test and folliculitis only in male patients [18]. The acronym SAPHO 
was defined as synovitis, acne, pustulosis, hyperostosis, and osteitis. Due to a lack of research 
SAPHO overlaps clinically with BD remains to be elucidated. Caravatti et al. published a case 






in BD (%) (different 
terms used in 
literature)
Comparisons according to 
certain variables
Ndiaye et al. [44] Senegal (2015) 50 PF: 30%, acneiform 
papules:12%




Patients with arthritic attacks: 
84% * Patients with no arthritic 
attacks: 16%
Demirseren et al. [30] Turkey (2014) 51 PPL: 64.7%
Davatchi et al. [46] Iran (1975–2014) 6075 PF: 53.2% Male vs Female: 60 vs 44.4% *
PPL, Papulopustular lesions; PF, Pseudofolliculitis; DVT: Deep vein thrombosis.
*Statistically significant (p < 0.05).
Table 2. Frequency of acneiform papulopustular lesions related to Behcet’s disease in different ethnic groups.
Acne and Acneiform Eruptions106
report in which the patient met all diagnostic criteria of both SAPHO and BD. This study 
shows that similar arthritis mechanism occurs between BD and SAPHO and also both of 
them consist of acne-like eruptions [52]. Due to necessity of further investigation, Yabe et al. 
reported two case reports and compared with other studies in literature. They manifested 
that SAPHO syndrome and BD referred as seronegative arthropathies and also SAPHO could 
be clinical overlap of BD [53]. However, Alli et al. could not find a statistically significant 
relationship between arthritis and PPL in SAPHO syndrome [37]. Thus, there is a need for to 
work harder in order to elucidate similar mechanisms.
4.3. Comparison of the PPL characteristics between BD and acne  
vulgaris/acneiform disorders
PPL of BD can easily be confused with the acneiform papular and pustular lesions of acne 
vulgaris. As everyone knows, typical acne vulgaris usually begins around first and second 
decades and is easily diagnosed. However, both diseases can occur in patients aged 20–40. 
As how importance is the early diagnosis for BD, clinicians should focus on their main 
 differentiation [54].
The PPL of BD patients are mainly known as sterile pustules, but some authors suggest that 
they contain a different type of bacteria than acne vulgaris lesions [7, 21]. Hatemi et al. studied 
58 BD patients and 37 acne patients, and obtained the culture of pustules. They suggested that 
Staphylococcus aureus and Prevotella spp. were significantly more common in pustules from BD 
patients, and coagulase-negative staphylococci in pustules from acne patients. Prevotella spp. 
was not cultured from the acne pustules. BD pustules thus have different types of bacteria, 
which results in a different pathogenesis [21].
BD is a neutrophilic dermatosis that is commonly based on vasculitic disorders, but acne 
vulgaris is a hyperfunction of sebaceous glands under hormonal control. PPL in BD has been 
observed mainly in the lower extremities and trunk, but acne vulgaris has been observed 
mainly in face, chest, and back. Alpsoy et al. researched on 100 patients (50 patients with BD, 
79 cases for control group including 21 patients with acne vulgaris) and consequently, it was 
found that the frequency of PPL in BD patients was 96% and the most common location was 
the trunk, whereas in the control group the frequency of PPL was 89% and the most common 
location was the face. The total numbers of PPL on the trunk, upper and lower extremities, 
and genitalia were higher in patients with BD than in controls [22]. Kutlubay et al. observed 
that papules and folliculitis on the back and the lower extremities in BD were higher than 
acne vulgaris group [27]. Prior clinical studies in literature comparing locations, types and 
numbers of PPL lesions between BD and acne vulgaris are summarized in Table 3.
As mentioned before, PPL of BD were evaluated using the International Study Group Criteria 
due to their 70% sensitivity and 76% specificity [13]. Davatchi et al. [46] determined that BD 
has dome-shaped pustule, not a sharp pustule like acne vulgaris. However, both of them 
resembled follicular lesions so that arguments continue about whether or not histopathological 
differentiation must be necessary via lesional skin biopsy for differential diagnosis. In the liter-
ature, there are some histopathological investigation studies of PPL in BD patients. As a result 
of these studies, there are numerous quandaries about the diagnostic histopathologic patterns 
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and regarding whether to include vasculitis or nonspecific folliculitis [23, 27, 55]. Comparison 
data of the histopathological and direct immunofluorescence findings of PPL between BD and 
other acneiform lesions consisting of acne vulgaris and folliculitis are summarized in Table 4.
When considering the histopathological findings of PPL in BD, Ergun et al. took samples, 
which were chosen as only fresh pustules from the legs and arms of 17 patients with BD and 
6 patients with acne vulgaris. Only 12% patients with BD revealed perivascular involvement 
without leucocytoclastic vasculitis and results stated that there was no differentiation between 
acne vulgaris and BD by histopathological evidence. They argued that there is no need to con-
References No. of patients Location, type and mean number of PPL
Alpsoy et al. [22] 50 BD/21 AV Face: 2.6 ± 2.8 in BD/7.5 ± 5.6* in AV;  Neck: 1.0 ± 1.4 in BD/2.3 ± 1.9* in 
AV;  Mean total number: 18.8 ± 15.9 in BD/28.3 ± 23.4* in AV
Kutlubay et al. [27] 58 BD/31 AV Face/papule: 4.41 ± 4.47 in BD/11.8 ± 13.4* in AV;  Face/pustule: 1.55 ± 
2.07 in BD/5.75 ± 5.1* in AV;  Face/comedone: 9.79 ± 14.8 in BD/42.5 ± 
43.7* in AV;  Back/papule: 8.73 ± 7.13* in BD/5.62 ± 5.77 in AV;  Back/
folliculitis: 0.58 ± 1.92* only in BD Lower extremity/folliculitis: 1.64 ± 
3.47* only in BD
AV, acne vulgaris; BD, Behcet’s disease; PPL, papulopustular lesions.
*Statistically significant (p < 0.05).
Table 3. Clinical studies comparing locations, types and numbers of papulopustular lesions between Behcet’s disease 
and acne vulgaris.
References Benchmarking acne 
vulgaris with PPL 
in BD







17 BD LV: 64.7% lesional/ 11.8%  
nonlesional;
Pustule: 17.6% lesional;
LympV: 5.9% lesional/ 11.8% 
non-lesional;
Mixed: 5.9% lesional/ 17.6% 
non-lesional;
MNC: 5.9% lesional/ 17.6% 
non-lesional;
PMN: 5.9% lesional/ 5.9% 
non-lesional;
IR on vessels: 70.9% 
lesional/ 23.5% 
non-lesional;
IgM: 52.9% lesional/ 
17.6% non-lesional;
IgG: 35.3% lesional; 
11.8% non-lesional;
C3: 41.2% lesional; 17.6% 
non-lesional




PPL of BD vs AV 17 BD, 6 AV In epidermis (intraepidermal 
pustule: 47.1% BD; spongiosis: 35.3% 
BD/16.7% AV; exocytosis: 11.8% BD; 
necrotic keratinocytes: 5.9% BD)
In follicle epithelium (plugging: 
58.9% BD/ 100% AV; rupture: 23.5% 
BD/16.7% AV; necrotic keratinocytes 
or epithelial necrosis: 11.8% 
BD/33.3% AV)
In dermis (endothelial swelling: 
23.5% BD/33.3% AV; nuclear dust: 
17.6% BD/16.7% AV)
Eccrine glands  (41.2% BD/33.3% AV)
–
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firm PPL of BD with biopsies [23]. Moreover, Chun et al. [55] also agreed on this hypothesis 
based on their research. More recently, Kutlubay et al. analyzed punch biopsy samples from 
58 BD and 31 acne vulgaris patients by two blinded pathologist. Both of them found vasculitis 
in the same patients in 7% of BD and 3% of acne vulgaris patients. Follicle-based pathology 
was detected in totally 87.6% (78/89 patients) and 82% (73/89 patients) in both the BD and AV 
References Benchmarking acne 
vulgaris with PPL 
in BD






PPL vs nonspecific 
follicular lesions
20 (23 PPL) LV: 13.04%; Perivascular infiltration: 
21.7%; Perivascular and interstitial 
infiltration: 8.7%; Perifollicular and 
perivascular infiltration: 39.1%; 




PPL of BD vs 
folliculitis/AV
18 BD 16 
control PPL (11 
folliculitis, 5 AV)
Pattern I: vasculitis (lymphocytic or 
leucocytoclastic) 
27.8% BD/ 0% control group;
Pattern II: folliculitis and/or 
perifolliculitis 
16.7% BD/ 50% control group; 
Pattern III: superficial and/or deep 
perivascular and/or interstitial 
dermatitis 
22.2% BD/ 18.8% control group
IR depositions on vessels; 
In 22.2% of BD patients 
(16.7% in pattern I, 5.6% 
in pattern II;  
in pattern I; 5.6% IgG, 
IgM, C3 and fibrinogen 
as quadruple conjugate, 
5.6% C3 and fibrinogen 
as double conjugate, 
5.6% only C3)/In 18.7% 
of control groups (6.2% 




PPL of BD vs AV 42 BD, 21 AV LV: 6.7% in BD*; LympV: 7.1% 
BD; Superficial perivascular and/
or interstitial infiltration: 35.7% 
BD/38.1% AV; superficial and deep 
perivascular and/or interstitial 
infiltration: 28.6% BD/19.0% AV; 





PPL of BD vs AV 58 BD, 31 AV PNL infiltration without folliculitis: 
1.7% BD/1.6% AV;
Mononuclear infiltration without 
folliculitis: 0.8% BD/4.8% AV;
Folliculitis/perifolliculitis: 85.3% 
BD,83.9% AV; LV:12.1% BD/9.7% AV;
Comedone formation: 39.6% 
BD/64.5% AV;
Intrafollicular abscess formation: 
62.1% BD/61.3% AV;
Presence of microorganisms, etc: 
13.8% BD/14.5% AV
–
AV, acne vulgaris; BD, Behcet’s disease; PPL, papulopustular lesions; LV, leucocytoclastic vasculitis; LympV, lymphocytic 
vasculitis; MNC, mononuclear cells; PMN, polymorphonuclear cells; Mixed, mixed cell infiltration; IR, Immunoreactant.
*statistically significant (p < 0.05).
Table 4. Histopathological and direct immunofluorescence findings for papulopustular lesions in Behcet's disease.
Acneiform Papulopustular Eruptions in Behçet's Disease
http://dx.doi.org/10.5772/65732
109
groups by both pathologists; controversially vessel-based pathology was rarely observed, 9% 
(10/89 patients) in both the BD and AV groups [27]. Therefore, they also claimed that there is 
no pathological difference between BD and acne vulgaris such as vasculitis.
On the other hand, Ilknur et al. evaluated the follicular and nonfollicular lesions from 18 
patients with BD and from 16 patients (11 with bacterial folliculitis, 5 with acne vulgaris) as 
a control group. They manifested that only the useful pattern for BD diagnosis was vasculitic 
changes which were not found in control group. The strength of this research is histopatho-
logical specimens were analyzed by two different pathologists for the first time, so the results 
were made with a consensus [25]. According to the study of Boyvat et al., the clinical features 
cannot be distinguishable for a BD diagnosis, but biopsy specimens must include  vessel-based 
neutrophilic reactions [24]. In another study, Kalkan et al. [26] found that 16.7% leukocyto-
clastic vasculitis and 7.1% lymphocytic vasculitis were present in BD patients although any 
vasculitic finding was not found in acne vulgaris patients. Furthermore, arguments still con-
tinue to clarify the exact pattern of PPL in BD. More assessments are needed to investigate.
If histopathological findings cannot provide any benefit for BD diagnosis, we may use 
immuno his to chemical techniques as an additional diagnostic test. In 2003, Alpsoy et al. 
evaluated 17 patients whose biopsies had taken from lesional and non lesional skin parts to 
study via immunological tools. The polyclonal antibodies including IgA, IgG, IgM, C3, and 
fibrin were measured, IgM deposition of thelesional skin was significantly higher than non 
lesional skin (52.9% and 17.6%, respectively); despite of that, there were no statistically sig-
nificant differences in terms of IgG, C3, and fibrin deposits on the vessels [55]. Subsequently, 
Ilknur et al. investigated the direct immunofluorescence results of 18 patients with BD and 
16 control patients in order to evaluate any deposition of immunoreactants on dermal blood 
vessels. They found no significant difference between the groups [25].
4.4. Management of PPL in BD
BD has now become a treatable disease, although it is not yet curable. The choice of treat-
ment is based on clinical features and the severity of the disease. Main treatment approach 
should be prevention of the severe organ damage. Recent guidelines could not establish a 
standard therapy for mucocutaneous lesions. A wide spectrum of agents can be used suc-
cessfully to heal and prevent the formation of new lesions. As our study specifies the PPL 
management, first-line treatment is topical ones such as corticosteroid or combination with 
corticosteroid and antibiotics. To support antibiotic use, it is reported that like Prevotella 
spp. and Staphylococcus aureus have been cultured in PPL. Although benzathin penicillin 
is the most commonly used one, minocycline is more effective than benzathin penicillin 
in  reducing of lesions. The systemic approach to BD treatment consists mainly of cortico-
steroids and colchicine. Corticosteroids are effective choices in almost all mucocutaneous 
lesions. They can be combined with other drugs such as colchicine, IFN-a or azathioprine. 
Guidelines recommend that corticosteroid administration begins with 40–60 mg/d for 1–2 
weeks and tapers the dosage over 4 weeks. However, this therapy has limitations due to its 
long-term side effects [57–59]. Corticosteroid treatment has been also a potent trigger for 
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acne and referred as steroid acne. Clinicians have to keep in mind that acneiform papulopus-
tular eruptions in BD may also appear as a result of steroid treatment. It is also important to 
know that steroid acne have some similarities and differences between Behcet’s pseudofol-
liculitis. Similarly, both of them mostly stay in trunk and extremities rather than face. At the 
same time, PPL in BD may arise as papules, pustules, and comedones at different stages of 
development. However, steroid acne usually stays as small folliculitis at the same stage in 
the proper area where the corticoid therapy is applied and it usually appears 2 weeks after 
the therapy has begun. Both of them resembled in neutrophilic involvement in the lesions 
but BD also has the vasculitic pattern. If the distinction can be made between true PPL and 
steroid acne in BD, management of the acneiform eruptions in these patients would be dif-
ferent and reasonable [60].
Colchicine is the one of the strongest medications for BD. Colchicine inhibits the chemo-
tactic activity and decreases the tumor necrosis factor-α, leukotrien-B4, cyclooxygenase-2 
activity, and prostoglandin-E2 levels. Mainly, it is approached in erythema nodosum 
and arthritis treatment for female patients. Colchicine combined with benzathine penicil-
lin increases the potency of the therapy. The lack of evidence in the efficacy of colchicine 
for treatment of mucocutaneous lesions could be related to relative lack of inappropriate 
researches. Moreover, IFN-a and etanercept treatment has been reported to decrease PPL 
frequency. Alternative therapy (dapson) has shown a significant capacity to diminish PPL. 
For severe lesions, azathioprine, pentoxifylline and thalidomide have demonstrated benefi-
cial effects [57–59].
5. Conclusion
According to the International Study Group criteria for BD diagnosis, skin lesions are 
restricted to erythema nodosum-like lesions, pseudofolliculitis, papulopustular lesions, and 
acneiform nodules. These lesions excepting erythema nodosum-like lesions are nonspecific 
and clinically confused with other acneiform papulopustular eruptions (e.g., acne vulgaris, 
bacterial folliculitis, steroid acne). Although earlier studies involve numerous quandaries 
regarding the diagnostic histopathologic pattern of BD (e.g., whether to include vasculitis or 
nonspecific folliculitis), it was reported recently that the determination of vasculitic changes 
in histopathological and direct immunofluorescence results might be useful in the differential 
diagnosis of patients suspected to have BD.
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